公司資料
Pfizer, Inc. 股價、新聞與催化劑
- 股票代碼:
- PFE
- 交易所:
- NYSE
- 產業:
- Biopharma, Oncology, Vaccines
- 所在地:
- United States
股票表現
28.12 USD (-1.40%)
收盤價
最後更新: 2026年10月1日
146B USD
市值
股價為何變動
截至 2026年10月1日，PFE 下跌 1.40%，收於 $28.12。目前新聞監測窗口內未發現新的同公司新聞。
公司概覽
Global Biopharmaceutical Company
Pfizer develops and commercializes medicines and vaccines across oncology, internal medicine, vaccines, and inflammation and immunology. Its portfolio combines internally discovered products with businesses and technologies acquired through transactions including Seagen, Biohaven, Arena Pharmaceuticals, and Global Blood Therapeutics.
Oncology and Antibody-Drug Conjugates
Pfizer's oncology portfolio includes Ibrance, Xtandi, Lorbrena, Braftovi, Talzenna, Padcev, Adcetris, Tivdak, and Elrexfio. The Seagen acquisition added a leading antibody-drug conjugate platform and commercial products, supporting development across breast, bladder, lung, hematologic, and other cancers through targeted agents and combination regimens.
Internal Medicine and Rare Disease
The internal-medicine business includes Eliquis in anticoagulation, Vyndaqel-family products in transthyretin amyloid cardiomyopathy, and medicines for cardiovascular, metabolic, and rare diseases. Pfizer also markets Hympavzi for hemophilia and is advancing additional programs in obesity, cardiometabolic disease, and genetically defined conditions.
Vaccines and Infectious Disease
Pfizer has a broad vaccine portfolio led by the Prevnar pneumococcal franchise, Abrysvo for respiratory syncytial virus, and Comirnaty for COVID-19. Research programs include higher-valency pneumococcal conjugate vaccines and next-generation vaccines intended to expand serotype coverage across pediatric and adult populations.
Inflammation and Immunology
The inflammation and immunology portfolio includes Xeljanz, Litfulo, Velsipity, and Cibinqo across rheumatologic, dermatologic, and gastrointestinal diseases. Pfizer is pursuing additional indications for these medicines, including nonsegmental vitiligo for Litfulo, while applying small-molecule and biologic approaches to immune-mediated conditions.
Obesity and Metabolic Pipeline
Pfizer is building an obesity portfolio around berobenatide, an injectable GLP-1 receptor agonist designed for monthly dosing, and additional internal and partnered candidates. The planned development program covers chronic weight management and obesity-related complications such as obstructive sleep apnea and knee osteoarthritis.
未來催化劑
- FDA PDUFA decision in the fourth quarter of 2026 on Talzenna plus Xtandi for HRR gene-altered metastatic castration-sensitive prostate cancer.
- Launch of a ten-study Phase 3 berobenatide development program during 2026 across chronic weight management and obesity-related comorbidities.
- Entry of Pfizer's fifth-generation 35-valent adult pneumococcal vaccine candidate into clinical development by the end of 2026, subject to regulatory alignment.
- Global regulatory filings for Litfulo in nonsegmental vitiligo based on positive Phase 3 TRANQUILLO and TRANQUILLO 2 results.
近期新聞
新聞標題由機器翻譯，詳情為英文原文。
- 01
相似股票
商業成熟度、治療領域或催化劑模式相近的同業公司。